Last updated on September 2017

Evaluation of the Safety Tolerability and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease

Brief description of study

This is a Phase 1b, open-label, dose-escalation, signal-finding, single center study. The study will evaluate the safety, tolerability, pharmacokinetics and short-term efficacy of MDGN-002 in adults with moderate to severe, active Crohn's disease who have previously failed anti-tumor necrosis factor alpha (anti-TNFα) treatment.

Clinical Study Identifier: NCT03169894


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Caitlin Walsh

The Center for Pediatric Inflammatory Bowel Disease, Children's Hospital of Philadelphia
Philadelphia, PA United States
  Connect »